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Abstract
Activation of coagulation pathways may contribute to risk for non-AIDS related conditions among
HIV positive patients. We measured tissue factor-dependent procoagulant activity on circulating
microparticles (MP-TF) in the plasma of 163 HIV positive participants, both untreated and treated,
with viral suppression. MP-TF activity was 39% lower among treated versus untreated participants
(p<0.001), which persisted in adjusted models (−36%; p=0.03). Among treated participants, MP-
TF activity correlated modestly with D-dimer (r=0.24; p=0.01), vWF (r=0.36; p<0.001), and IL-6
(r=0.20; p=0.04) levels. Future research should focus on mechanisms driving residual functional
TF activity and whether these alterations have clinical consequences for non-AIDS defining
complications.
INTRODUCTION
The spectrum of clinical disease among contemporary HIV positive patients receiving
effective treatment with antiretroviral therapy (ART) now more commonly consists of non-
AIDS defining chronic conditions such as cardiovascular disease.12 Plasma D-dimer, a
marker of coagulation activity, strongly predicts risk for all-cause mortality (largely non-
AIDS related) as well as specific conditions like CVD and thromboembolic events among
HIV patients.3–7 In addition, D-dimer levels are correlated with HIV viral replication after
starting or stopping ART, but remain elevated among treated patients when compared to
uninfected controls.689 Currently, mechanisms underlying persistent HIV-related
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abnormalities in coagulation biology, and the potential consequences for non-AIDS related
clinical risk, remain poorly understood.
Tissue factor (TF) is a transmembrane protein that when complexed with factor VII(a), is
responsible for initiating coagulation through activation of the extrinsic pathway. Circulating
TF exists on cell surfaces (e.g., activated monocytes), as soluble cell-free TF in plasma
(where it is largely inactive in coagulation), and on cell-derived microparticles (MP). MPs
are membrane-encapsulated vesicles released from activated or apoptotic cells that contain
and express surface proteins derived from the parent cell.10 Though TF positive MPs (MP-
TF) constitute only a small fraction of circulating TF, they likely represent a functionally
active form of TF given their origin from activated cells (e.g., released form monocytes in
response to endotoxemia).1011 In this report we study the effect of ART treatment on MP-TF
procoagulant activity, and explore associations between MP-TF activity with biomarkers of




Participants with HIV infection were recruited from 2007 to 2011 as part of ongoing
research protocols at Hennepin County Medical Center (HCMC) HIV clinic in Minneapolis,
MN. Plasma biomarkers of inflammation and coagulation had previously been measured
among most of these participants. MP-TF activity was assessed for this study using stored
specimens from participants who were either: a) naïve to treatment or off ART for ≥1 year
(i.e., ‘untreated’), or b) receiving ART with HIV viral load <200 copies/mL for ≥6 months
(i.e., ‘treated’). Patients were excluded for presence of a current bacterial infection,
pregnancy, or known CVD. Study measures were obtained at a single study visit.
Framingham Risk Score (FRS) for 10 year coronary heart disease risk was estimated using
published algorithms.12 All study protocols, including use of stored specimens for future
research, were approved by the HCMC human subject research committee, and participants
underwent written informed consent prior to enrollment.
Laboratory Measures
Plasma specimens were collected using EDTA (ethylenediaminetetraacetic acid) tubes and
processed within 30 minutes of collection and frozen at −70°C until analysis. Plasma was
isolated after a 2500g spin for 15 minutes in a refrigerated centrifuged at 4°C. Measures
obtained from fresh blood at HCMC clinical laboratory included: HIV RNA level,
serologies for hepatitis B and C, total cholesterol, low-density lipoprotein cholesterol (LDL-
C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. All samples were
handled in a blinded fashion.
D-dimer levels, interleukin-6 (IL-6), and high sensitivity CRP (hsCRP) were measured using
methods previously described,13 and von Willebrand factor (vWF) levels were measured on
Stago STA-R analyzer (Stago Diagnostics, Parsipanny NJ), at the Laboratory for Clinical
Biochemistry Research at the University of Vermont. These markers were chosen to assess
coagulation activity and inflammation, and because they have been associated with clinical
risk for CVD and all-cause mortality in HIV infected and uninfected populations.6714–16
MP-TF activity was measured as previously reported,17 on MPs isolated from stored EDTA
plasma by performing another centrifugation at 20,000g for 30 minutes at 4oC. The MP
pellet was re-suspended in HBSA (20mM HEPES, 120mM NaCl, 1mg/ml) via mild
sonication. A previously described two stage chromogenic assay was employed with the
following modifications: 1) MPs were incubated for 2 hours with 2.5mM CaCl2, 1nM FVIIa
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and 150nM FX in the presence and absence of a TF blocking antibody, 2) Absorbance
measurements were made every 30 seconds for 30 minutes after the addition of EDTA and
FXa chromogenic substrate (Pefachrome 8595, Centerchem, Norwalk, CT).18 MP-TF
activity was calculated in relation to an Innovin™ tissue factor standard.
Statistical Methods
Descriptive statistics are reported as means with standard deviation (SD) and medians with
inter-quartile range (IQR). Wilcoxon rank tests and the chi square test for categorical
variables were used to compare characteristics of the untreated and ART-treated groups. For
comparisons between groups, the relative percent difference (with 95% confidence interval)
was obtained by exponentiating the mean difference on the natural log scale using
generalized linear models. Fully adjusted models included the following covariates: age,
gender, race/ethnicity, smoking status, co-infection with hepatitis B/C, prior AIDS, current
CD4 count, total-to-HDL-C ratio and lipid lowering therapy. Hepatitis B/C co-infection was
chosen over injection drug use (IDU) in covariate models as hepatitis B/C co-infection is
more likely to influence the degree of current systemic inflammation, and findings were
similar with and without inclusion of IDU in multivariate models. Total-to-HDL-C was
included over other lipid parameters given the strong association with clinical event risk,1920
and that these 2 lipid measures differed the most between groups. Determinants of residual
MP-TF activity were then explored among treated participants. Correlations were assessed
using non-parametric rank tests due non-normal distribution of data. The level of
significance was defined as p<0.05, and all analyses were conducted with SAS (version 9.2)
and R statistical software (Version 2.10.1; http://www.cran.r-project.org).
RESULTS
Study Sample
Among the 163 HIV positive participants, 54 were untreated and 109 were receiving ART
with a suppressed viral load. Demographic and clinical characteristics are presented in Table
1. Compared with untreated participants, those receiving ART were older, had a higher CD4
count, a higher proportion with a prior AIDS event, and a lower proportion with a history of
IDU or who currently smoked cigarettes. Overall, traditional cardiovascular disease risk
factors were more abnormal for treated versus untreated participants as indicated by 10-year
FRS, use of lipid lowering drugs and cholesterol levels. Among treated participants, 51%
were taking tenofovir disoproxil fumarate (DF), 50% were taking abacavir, 27% were taking
a non-nucleoside reverse transcriptase inhibitor (efavirenz for 23%), 12% were taking
raltegravir, and 49% were taking a protease inhibitor (26% atazanavir, 8% lopinavir, and 6%
darunavir).
Comparison Between Untreated and ART-Treated Participants
Median values for MP-TF activity and other plasma biomarkers, including differences by
ART use from unadjusted comparisons, are presented in Table 1. When compared to
untreated participants, treated participants have 39% lower MP-TF activity, 52% lower D-
dimer, 41% lower vWF, and 36% lower IL-6, but hsCRP levels were not significantly
different. In fully adjusted models, differences were similar for MP-TF activity (36% lower;
p=0.03), D-dimer (61% lower; p<0.001), wWF (37% lower; p<0.001), IL-6 (49% lower;
p<0.001), and hsCRP (47% lower; p=0.02).
MP-TF Activity, Co-morbid Disease, Inflammation, and Coagulation Activity
Among untreated participants, MP-TF activity was higher for those with hepatitis B or C co-
infection (74%; p=0.03), and was correlated with age (r=0.30; p=0.03), 10-year FRS
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(r=0.34; p=0.01), and current CD4 count (r=0.43; p=0.001). In contrast, among treated
participants, MP-TF activity was not correlated with age, 10-year FRS or current CD4
count, but was 28% lower (p=0.09) among those taking lipid-lowering medication versus
not.
Finally, we then explored associations between MP-TF activity among treated patients with
plasma biomarker levels to see if TF activity corresponded to residual abnormalities in
biomarkers reflecting ongoing inflammation and coagulation. Scatter plots with correlations
between MP-TF activity and inflammation and coagulation biomarkers are presented in
Figure 1. In linear regression models, the change in log-e MP-TF activity for each 1 log-e
increase in biomarker level was 0.19 for D-dimer (95% CI −0.02, 0.41; p=0.08), 0.84 for
vWF (95% CI 0.44, 1.23; p<0.001), 0.26 for IL-6 (95% CI 0.02, 0.50; p=0.04), and 0.09 for
hsCRP (95% CI −0.06, 0.24; p=0.22). Corresponding associations tended to be stronger in
fully adjusted models at 0.31 for D-dimer (p=0.01), 0.86 for vWF (p<0.001), 0.32 for IL-6
(p=0.02), and 0.21 for hsCRP (p=0.01).
DISCUSSION
Activation of coagulation pathways has been identified as a potential mechanism
contributing to risk for non-AIDS-defining complications among HIV positive patients.4–6
We assessed the functional procoagulant activity of MP-TF, an active form of circulating
cell-free TF, and determined that ART treatment with viral suppression was associated with
lower TF pro-coagulant activity. Coagulation activity, as assessed by D-dimer levels, is
persistently elevated among HIV-infected persons, despite viral suppression, though
questions remain about the mechanisms up-regulating coagulation pathways.9 Our findings
that residual MP-TF activity among treated patients is associated with biomarkers of
inflammation and coagulation is consistent with the hypothesis that residual inflammation
may be contributing to HIV-related coagulation abnormalities through increased circulating
TF activity.
In a sentinel study by Funderburg et. al., monocyte expression of TF was increased between
HIV infected versus uninfected persons and also correlated directly with HIV RNA and D-
dimer levels.21 The authors subsequently reported that HIV increases the frequency of
‘activated’ monocyte phenotypes (CD14+/-CD16+), which express TF at high levels.2122
Monocyte and tissue macrophage activation is an important mediator of coagulation and
disease risk (e.g., premature atherosclerosis),2324 and sCD14, a plasma marker of monocyte
activation, is an independent predictor of mortality (largely non-AIDS related) among HIV
positive patients.25 Circulating MP-TF typically originate from monocytes that express TF,
and our findings describing associations between MP-TF procoagulant activity with D-
dimer and vWF levels are consistent with the notion that activation of TF-pathways is an
important component of HIV-related coagulation abnormalities.
The clinical significance of MP-TF activity among HIV positive patients is unknown, but is
potentially important given IL-6 and D-dimer associations with clinical risk. Epidemiologic
data show that these plasma biomarkers are elevated among HIV infected persons, even
after viral suppression, and elevated levels predict increased risk for myocardial infarction
and all-cause mortality.4–79 Specifically, in the SMART (Strategic Timing of AntiRetroviral
Therapy) study, mortality risk associations with IL-6 and D-dimer were robust, present for
those on and off ART, present for events in short and longer (>2 years) term, and were more
extreme than what has been reported in uninfected populations.62627 The hypothesis that
persistent up-regulation of TF pathways in HIV patients explains, at least in part, D-dimer
clinical risk prediction requires validation with additional measures of TF activity in larger
studies.
Baker et al. Page 4













The vast majority of TF in circulating blood is contained within mononuclear cells,1011 and
the inability to assess this fraction of peripheral blood was a limitation of our study. Newer
methods that assess TF activity in whole blood (i.e., reflecting both cell-free and cell-
associated activity) may now be applied to study epidemiologic associations with clinical
event risk.10 Similarly, we were not able to determine whether monocyte activation is
driving TF activity, or accounts for the associations with inflammatory biomarkers.
Additional limitations of our study include the cross-sectional design and lack of an HIV
uninfected control group. Although median MP-TF activity for both treated and untreated
participants are higher that what we’ve found in healthy controls while developing the assay,
comparisons of TF activity between treated HIV positive patients and uninfected persons
need to account for additional confounding factors and this will be important to clarify in
future studies.
In summary, ART treatment is associated with reduced MP-TF pro-coagulant activity,
though residual activity among virally suppressed patients is related to ongoing
inflammation and may be an important contributor to coagulation abnormalities. Future
research should focus on the underlying mechanisms driving TF activity and whether these
alterations contribute to clinical event risk.
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Figure 1. Correlations Between MP-TF Activity and Plasma Biomarker Levels
Legend: Scatter plot with trend line describes the correlation between MP-TF activity and
D-dimer (a; square), vWF (b; triangle), IL-6 (c; circle) and hsCRP (d; diamond) levels.
Spearman’s rank correlation coefficient and p-value are reported.
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TABLE 1




Age, median years (IQR) 41 (31, 45) 47 (43, 54) <0.001
Male Gender, # (%) 45 (83) 98 (90) 0.23
Race/Ethnicity
  White, # (%)
  African American, # (%)








Current Smoker, # (%) 35 (65) 48 (44) 0.01
Prior IDU, # (%) 17 (35) 8 (7) <0.001
Hepatitis B or C, # (%) 14 (26) 15 (14) 0.12
Prior AIDS, # (%) 6 (12) 48 (47) <0.001
BMI, median kg/m2 (IQR) 26 (23, 29) 27 (24, 29) 0.65
Diabetes, # (%) 3(6) 9(8) 0.81
Blood pressure medication, # (%) 11 (20) 17 (16) 0.44
Lipid lowering medication, # (%) 1 (3) 30 (28) 0.001
10-year FRS, median % (IQR) 5.14 (1.23, 9.15) 7.13 (4.51, 10.44) 0.008
ART regimen
  Tenofovir, # (%)
  NNRTI, # (%)











CD4+ count, median cells/mm3 (IQR) 342 (259, 446) 522 (377, 745) <0.001
HIV RNA, median log10 copies/mL (IQR) 4.2 (3.9, 4.7) -- --
Total Chol./HDL-C, median (IQR) 4.0 (3.3, 5.5) 4.0 (3.4, 5.2) 0.25
Total Cholesterol, median mg/dL (IQR) 162 (129, 185) 185 (167, 212) <0.001
LDL-C, median mg/dL (IQR) 88 (71, 112) 103 (85, 123) 0.02
HDL-C, median mg/dL (IQR) 37 (30, 48) 46 (36, 54) <0.001
Triglycerides, median mg/dL (IQR) 118 (78, 155) 142 (99, 226) 0.002
MP-TF activity, median pg/mL (IQR) 0.35 (0.24, 0.54) 0.22 (0.14, 0.34) <0.001
D-dimer, median μg/mL (IQR) 0.35 (0.19, 0.57) 0.15 (0.11, 0.25) <0.001
vWF, median (IQR) 224.0 (178.5, 303.0) 131.5 (107.0, 181.0) <0.001
IL-6, median pg/mL (IQR) 2.35 (1.53, 4.64) 1.67 (1.17, 2.35) <0.001
hsCRP, median μg/mL (IQR) 1.99 (0.80, 5.18) 1.66 (0.83, 3.74) 0.02
*
p-value for comparison by ART use; IDU=injection drug use; BMI=body mass index; FRS=Framingham risk score; NNRTI=non-nucleoside
reverse transcriptase inhibitor; PI=protease inhibitor; LDL-C=low-density lipoprotein cholesterol; HDL-C=high-density lipoprotein cholesterol;
MP-TF= microparticles expressing active tissue factor; IL=6=interleukin-6; hsCRP=high sensitivity C-reactive protein; sICAM-1=soluble
intercellular adhesion molecule; vWF=von Willebrand Factor
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